

Clinical trials of exenatide once monthly

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
exenatide once monthly vs weekly exenatide			
phase 2 exenatide once monthly <i>unpublished</i> n=121 follow-up: 20 weeks	exenatide once monthly at a low, medium or high dose, each administered once every four weeks, for a total of 20 weeks versus exenatide 2mg once weekly	adults with type 2 diabetes who were not achieving adequate glucose control using diet and exercise alone or with a stable regimen of metformin, pioglitazone, or both	Parallel groups open

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>
- antidiabetic drugs for diabetes type 2 in patients with insufficient glycaemic control with bitherapy at <http://www.trialresultscenter.org/go-Q511>

References

phase 2 exenatide once monthly, :
unpublished

Entry terms: exenatide, exenatide, bydureon, exendin-4, Ex4 peptide, exendin 4, AC 2993 LAR, Byetta, AC 2993,